The Oncologist 2012;17:16–22; doi:10.1634/theoncologist.2012-S1-16
Due to an editing error, Figure 3 was labeled incorrectly. The corrected figure appears below. The publisher regrets the error.
Figure 3.
Cabazitaxel improves overall survival versus mitoxantrone regardless of age. Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; PSA, prostate-specific antigen. Adapted from de Bono JS, Outard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010;376:1147–1154, with permission.